Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (RPID) provides automated microbial quality control solutions for pharmaceutical manufacturers and life sciences organizations. This page aggregates official announcements, operational updates, and strategic developments impacting the company’s market position.
Access timely updates on RPID’s Growth Direct platform enhancements, regulatory compliance milestones, and industry partnerships. Investors will find earnings reports, management commentary, and manufacturing efficiency initiatives critical for evaluating the company’s performance in microbial detection automation.
Key updates include product launch details, intellectual property developments, and operational expansions within regulated healthcare markets. Content reflects RPID’s focus on reducing contamination risks and improving testing workflows through automated solutions.
Bookmark this page for structured access to RPID’s latest news stream, including analysis of market trends affecting quality control automation demand. Verify time-sensitive decisions against primary source materials linked where available.
Rapid Micro Biosystems (Nasdaq: RPID) has announced its preliminary unaudited revenue for Q4 2021, estimating total revenue between $4.7 million and $5.2 million, with commercial revenue between $4.5 million and $4.9 million. For the full year 2021, total revenue is expected at $22.8 to $23.3 million. Looking ahead, the company projects 2022 commercial revenue of $27 million to $32 million, representing growth of 25% to 50%. Despite challenges from COVID-19, Rapid Micro secured growth in recurring revenue, expecting a 90% increase in the last quarter of 2021.
Rapid Micro Biosystems (Nasdaq: RPID) announced the appointment of Inese Lowenstein to its Board of Directors, bringing extensive leadership experience from companies like Danaher and Merck. CEO Robert Spignesi expressed enthusiasm, noting Lowenstein's track record in customer-focused innovation and strategic growth. Her expertise in life sciences is expected to enhance the company’s mission to be a leader in microbial quality control. Lowenstein has over 20 years of experience in various leadership roles, reinforcing Rapid Micro's commitment to innovative healthcare solutions.
Rapid Micro Biosystems reported third quarter 2021 revenues of $6.9 million, with commercial revenue at $6.3 million, a 27% increase year-over-year. The company reaffirmed its full-year commercial revenue outlook of at least $24.0 million, indicating 70% growth over 2020. Recurring commercial revenue surged by 154% to $2.2 million. Despite these positive trends, net loss widened to ($25.0 million) from ($8.5 million) in Q3 2020, largely due to increased operating costs and charges related to the IPO. Cash on hand stood at $220 million.
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021. CEO Rob Spignesi and CFO Sean Wirtjes will lead a 30-minute Q&A session at 6:20 am PT/9:20 am ET. A live webcast will be available on the company's website and archived for 90 days. Rapid Micro specializes in automation solutions for healthcare manufacturing, enhancing the efficiency of microbial quality control testing. Its flagship Growth Direct® System modernizes testing workflows in pharmaceutical manufacturing, ensuring safe product releases.
Rapid Micro Biosystems (Nasdaq: RPID) will release its third quarter 2021 financial results on November 11, 2021, after market close. A conference call is scheduled for November 12, 2021, at 5:00 AM PT, where company management will discuss the results. The call will be accessible via live webcast on their website and archived for 90 days. Rapid Micro provides automation solutions to enhance the production and release of healthcare products, including biologics and vaccines, while ensuring compliance with quality control regulations.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) has appointed Andy Keys as Chief Commercial Officer, effective October 1, 2021. Keys, a veteran with over twenty years in the life sciences sector, previously served at Quanterix Corporation. His expertise will enhance Rapid Micro's global sales, service, and validation teams. Key highlights include the company's flagship Growth Direct® System, which automates microbial quality control in pharmaceutical manufacturing, promising faster results and improved efficiency in healthcare product releases.
Rapid Micro Biosystems (Nasdaq: RPID) announced its participation in the 2021 Parenteral Drug Association Pharmaceutical Microbiology Conference from October 4-6. The company will showcase its Growth Direct® System, which enhances microbial quality control in pharmaceutical manufacturing. Key achievements include a successful IPO, regulatory approvals in Europe and the U.S., and the sale of its one millionth consumable. Attendees can preview a new rapid sterility test and access informative resources on quality control.
Rapid Micro Biosystems (Nasdaq: RPID) announced its inclusion in the Russell 2000®, Russell 3000®, and Russell Microcap® indexes, effective September 20, 2021. This membership is based on market-capitalization rankings and style attributes, remaining effective for a year. CEO Rob Spignesi noted that this inclusion will enhance stock visibility in the investment community, aiding the company’s mission to improve microbial quality control in pharmaceutical manufacturing. The company specializes in automation solutions for healthcare product manufacturing, with a focus on safety and efficiency.
Rapid Micro Biosystems (Nasdaq: RPID) announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021. CEO Rob Spignesi and CFO Sean Wirtjes will engage in a 30-minute virtual Q&A session starting at 5:00 AM PT (8:00 AM ET). Investors can access the live webcast on the company’s website, which will be archived for 90 days post-event. The company specializes in automation solutions for healthcare products, enhancing microbial quality control testing in pharmaceutical manufacturing.
Rapid Micro Biosystems reported second quarter 2021 commercial revenue of $5.7 million, reflecting 135% year-over-year growth. The company expects full-year revenue to reach at least $24 million, a growth of 70% from 2020. Cumulative system placements increased to 103 with 8 new systems installed. Recurring commercial revenue rose to $1.9 million, up 91% year-over-year. However, net loss for the quarter was $11.8 million, compared to $9.3 million a year earlier, primarily due to increased operating expenses.
FAQ
What is the current stock price of Rapid Micro Biosystems (RPID)?
What is the market cap of Rapid Micro Biosystems (RPID)?
